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Abstract
Background: Respiratory distress syndrome remains a significant problem among premature infants. Mechanical
ventilation through an endotracheal tube remains the mainstay of respiratory support but may be associated with
lung injury and the development of chronic lung disease of prematurity. Efforts are needed to reduce the duration
of mechanical ventilation in favour of less invasive forms of respiratory support and to improve rates of successful
extubation.
Non-invasive respiratory support has been demonstrated to be less injurious to the premature lung. Standard
practice is to use nasal continuous positive airway pressure (n-CPAP) following extubation to support the baby’s
breathing. Many clinicians also use nasal biphasic positive airway pressure (n-BiPAP) in efforts to improve rates of
successful extubation. However, there is currently no evidence that this confers any advantage over conventional
nasal continuous positive airway pressure.
Methods: We propose an unblinded multi-centre randomised trial comparing n-CPAP with n-BiPAP in babies born
before 30 weeks’ gestation and less than two weeks old. Babies with congenital abnormalities and severe intra-
ventricular haemorrhage will be excluded. 540 babies admitted to neonatal centres in England will be randomised
at the time of first extubation attempt. The primary aim of this study is to compare the rate of extubation failure
within 48 hours following the first attempt at extubation. The secondary aims are to compare the effect of n-BiPAP
and n-CPAP on the following outcomes:
1. Maintenance of successful extubation for 7 days post extubation
2. Oxygen requirement at 28 days of age and at 36 weeks’ corrected gestational age
3. Total days on ventilator, n-CPAP/n-BiPAP
4. Number of ventilator days following first extubation attempt
5. pH and partial pressure of carbon dioxide in the first post extubation blood gas
6. Duration of hospital stay
7. Rate of abdominal distension requiring cessation of feeds
8. Rate of apnoea and bradycardia
9. The age at transfer back to referral centre in days
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Background
Our working hypothesis is that preterm infants born
before 30 weeks’ gestation and less than two weeks old
when extubated on to nasal biphasic positive airway
pressure (n-BiPAP) will have a lower risk of extubation
failure than infants extubated on to single level, nasal
continuous positive airway pressure (n-CPAP).
Respiratory distress syndrome due to surfactant defi-
ciency is almost invariable in infants born at less than
28 weeks’ gestation and remains a significant problem in
infants born up to 34 weeks’ gestation. Mechanical ven-
tilation is the mainstay of treatment in this condition
and may be required for prolonged periods of time
extending to several weeks. Mechanical ventilation
through an endotracheal tube is associated with ventila-
tor associated lung injury which may be a significant
factor in the development of chronic lung disease of
prematurity (Bronchopulmonary dysplasia) - a condition
associated with significant morbidity and mortality
among preterm infants. Efforts have been made to
reduce dependence on mechanical ventilation using less
invasive forms of respiratory support such as nasal con-
tinuous positive airway pressure (n-CPAP). In this study
we aim to determine if the use of nasal biphasic positive
airway pressure (n-BiPAP) is more effective than single
level variable flow n-CPAP in preventing extubation fail-
ure in babies born before 30 weeks’ gestation and less
than 2 weeks old.
n-CPAP has previously been shown to reduce the risk
of extubation failure among preterm infants following
extubation from mechanical ventilation. However, in
around 25% of infants attempts at extubation fail [1].
Non-invasive respiratory support has been demonstrated
to be less injurious to the preterm lung [2]. Efforts
directed to minimise the exposure to or duration of
mechanical ventilation in preterm infants have demon-
strated the feasibility of early n-CPAP support among
extremely preterm infants [3]. In this study, we hypothe-
sise that there can be a further 10% reduction in extuba-
tion failures using n-BiPAP compared with n-CPAP.
Nasal Intermittent Positive Pressure Ventilation
(NIPPV) has been used as respiratory support post extu-
bation and there is evidence supporting the superiority
of NIPPV over conventional n-CPAP in avoiding re-
intubation in preterm infants [4]. Infants with birth
weight less than 2000 g and mild surfactant deficient
lung disease demonstrated reduced work of breathing
with synchronised NIPPV compared with conventional
n-CPAP [5]. Both of these studies involved the use of
the Infant Star ventilator providing continuous flow
CPAP with a Star Synch abdominal capsule to deliver
synchronised NIPPV. The provision of synchronised
NIPPV requires a ventilator capable of delivering this
mode of support. The Infant Flow Advance offers a less
complex/invasive method for the delivery of n-CPAP/n-
BiPAP. n-CPAP with the Infant Flow Driver (a variable
flow device) has also been shown to be more effective
than CPAP delivered using a continuous flow device in
improving oxygenation and reducing work of breathing
(see below).
The Infant Flow Advance delivers positive pressure at
t h en o s ea tt w os e tp r e s s u r el e v e l so rn - B i P A P .T h e
upper pressure setting is set 3 to 5 cm of water above
the base pressure and is delivered for a set “inspiratory”
time and a set “rate”.W i t hn - B i P A P ,t h e r ei sn os y n -
chronisation with the infant’s respiratory effort; the
infant continues to breathe spontaneously throughout
the periods of baseline and upper pressure delivery.
There have been two published trials to date which
describes the use of n-BiPAP in preterm infants [6,7].
Migliori et al performed an unblinded crossover study
comparing four alternating phases of n-CPAP and n-
BiPAP in twenty infants (gestational ages 24 to 31
weeks) within 6 hours of weaning from mechanical ven-
tilation. Significant improvements in oxygen saturations
and transcutaneous partial pressure of oxygen and car-
bon dioxide were noted during the n-BiPAP phases.
There was also a significant reduction in spontaneous
respiratory rate during the n-BiPAP phases. Lista et al
conducted a randomised control trial of 40 babies com-
paring the use of n-BiPAP with n-CPAP in premature
infants following Intubation-Surfactant-Extubation
(InSurE) approach [7]. They showed a significant reduc-
tion in duration of respiratory support, duration of oxy-
gen dependency and gestational age at discharge in the
group receiving n-BiPAP [7].
The most commonly used method for providing n-
CPAP in the UK is the Infant Flow Driver, which pro-
vides variable flow CPAP support. The Infant Flow Dri-
ver is a device which generates positive pressure at the
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with variations in flow/pressure within the nose itself,
reflecting the infant’s respiratory activity [8]. In this way,
there is variable flow, according to the phase of the
infant’s spontaneous respiratory effort. Prior evidence
has demonstrated that n-CPAP delivered using an Infant
Flow Driver is more effective both at recruiting lung
volume and reducing the work of breathing in preterm
infants compared with continuous flow devices [9,10].
The Infant Star ventilator delivers continuous flow n-
CPAP, so the published comparisons between n-CPAP
and synchronised NIPPV cited above may not be
directly applicable to variable flow n-BiPAP provided
using the Infant Flow Advance. The Infant Flow
Advance delivers bi-level pressure by increasing the flow
into the inspiratory limb of the circuit by up to 5 litres/
minute (depending on the desired pressure). This
increased flow enters the circuit proximal to the humi-
difier and there is an intrinsic time lag in delivering the
increased pressure (the rise time is at best “ < 1 second”
- internal communication from Viasys Healthcare),
which poses some doubt over whether effective synchro-
nisation with the infant’s inspiratory effort is feasible
and whether the additional complication of an abdom-
inal capsule to facilitate attempts at synchronisation is
necessary.
We therefore seek to compare the use of n-BiPAP
with conventional variable flow n-CPAP using the Infant
Flow Advance for respiratory support post extubation in
preterm infants born before 30 weeks’ gestation.
Relevance of the study to patients and service providers
The proposed study will be the first randomised trial
that will aim to compare the effectiveness of n-BiPAP
vs. n-CPAP in preventing extubation failure in prema-
ture babies born before 30 weeks’ gestation and less
than two weeks old. It will allow clinicians to have an
evidence based approach to the use of n-BiPAP under
these circumstances. Currently, the device is often used
with shorter ‘inspiratory times’ which significantly com-
promises its performance (S Mitchell, personal commu-
nication) and without good evidence to support either
its benefit or its safety.
If our hypothesis is proved correct and the use of n-
BiPAP improves the chances of successful extubation,
then the regular use of n-BiPAP would reduce the num-
ber of ventilator days in preterm infants. Reducing the
number of ventilator days is one way of minimising
chronic lung injury in premature infants. Earlier wean-
ing and hence the reduction in number of ventilator
days could have a significant positive impact on neona-
tal services & resources.
In the UK, facilities for the mechanical ventilation of
extremely premature infants tend to be concentrated at
neonatal tertiary referral centres in the National Health
Service. Once infants are successfully managed off the
ventilator they are transferred back to hospitals closer to
home. Reduction in ventilator days would allow earlier
transfer back to local hospitals with benefits to neonatal
service provision and to families.
In England, 7000 preterm infants are born each year
at high risk of developing chronic lung disease of pre-
maturity/bronchopulmonary dysplasia. This condition is
associated with significant morbidity and mortality.
A b o u th a l fo fa f f e c t e di n f a n ts continue to need supple-
mental oxygen at 36 weeks’ gestation. The duration of
ventilation during the newborn period is one of the
aetiological factors involved in the development of this
condition. Reduction in extubation failures and number
of days on the mechanical ventilator may minimise ven-
tilator associated lung injury and reduce this contribu-
tion to the development of chronic lung disease of
prematurity. By using the Infant Flow Advance, this
study is comparing two methods of delivering non-inva-
s i v es u p p o r tu s i n gt h es a m ew i d e l ya v a i l a b l ed e v i c ei n
this group of infants.
Methods
Aims
The primary aim of this study is to compare the risk of
extubation failures for 48 hours after the first extubation
comparing the use of n-BiPAP or n-CPAP in infants
born before 30 weeks’ gestation and less than two weeks
old.
Study design
This will be an unblinded multi-centre randomised trial
of n-BIPAP vs. n-CPAP in infants born before 30 weeks’
gestation and less than two weeks old.
Inclusion criteria
Infants satisfying the following inclusion criteria will be
eligible to participate:
(1) Born before 30 weeks’ gestation (and)
(2) Ventilated through an endotracheal tube (and)
(3) Less than two weeks old (and)
(4) Has not had first attempt at extubation (and)
(5) Parental consent has been obtained
Exclusion criteria
Infants with the following exclusion criteria will be not
be eligible to participate:
(1) Presence of major congenital malformations
(2) Presence of neuromuscular disease
(3) Presence of known upper respiratory tract
abnormalities
(4) Infants requiring surgery and likely to be within 7
days post-operative at the point of extubation.
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enchymal extension.
Primary outcome measure
Failure of extubation during the first 48 hours post-
extubation will be used as the primary outcome mea-
sure. 48 hours will be calculated from the hour of extu-
bation. Failure of extubation has been defined later
under ‘Criteria for failure of extubation’.W eh a v ec h o -
sen ‘Failure of extubation’ as our primary outcome mea-
sure to maintain similarity with previous trials
conducted using NIPPV. We will also measure the fol-
lowing secondary outcome measures.
Secondary outcome measures
(1) Maintenance of successful extubation for 7 days
from the hour of extubation
(2) Total days on ventilator, n-CPAP/n-BiPAP (any-
time requiring respiratory support during a 24 hour
clock will be counted as a day).
(3) Number of ventilator days following first extuba-
tion attempt (anytime requiring respiratory support dur-
ing a 24 hour clock will be counted as a day).
(4) Oxygen requirement at 28 days of age and at 36
weeks’ corrected gestation
(5) pH, partial pressure of carbon dioxide in the first
post extubation gas
(6) Duration of hospitalisation
(7) Rates of abdominal distension requiring cessation
of feeds for 7 days post extubation
(8) Rate of apnoea and bradycardia expressed as
events per hour during the 48 hours following
extubation
(9) Age at transfer back to referral centre in days
(10) Adverse events as described later
Sample size
A sample size of 270 in each group will have 80% power
to detect a 10% reduction in the rates of extubation fail-
u r ef r o m2 5 %i nt h en - C P A Pg r o u pt o1 5 %i nt h en -
BiPAP group at a 0.05 two-sided significance level. A
10% reduction in extubation failure rate would be clini-
cally significant and could support a change in practice
to using n-BiPAP as first line treatment post-extubation.
Existing meta-analyses of trials comparing NIPPV and
n-CPAP had around 80 babies in each arm.
Recruitment
Some preliminary written and oral information will, when-
ever possible, be offered to parents prior to birth if the
baby is likely to be eligible. Additional information will be
given once the baby has been born. Informed written con-
sent will be sought from a parent only after they have
been given a full oral and written explanation of the study.
Sufficient time will be provided for consent. In most
circumstances it will be possible to provide 24 hours
time for parents to make their decision. Occasionally,
babies may be ready to come off the ventilator quickly.
Under those circumstances less time may be available
for parents to decide. Since both treatments are used in
routine care we anticipate that this will not place par-
ents under undue pressure.
Where there is sufficient time between recruitment
and randomisation, parents will be offered an early
appointment with the Principal Investigator or delegated
deputy who will meet with them to ensure that they
understand the trial procedures and continue to consent
to participate in the trial. At all stages it will be made
clear to the parents that they remain free to withdraw
their baby from the study at any time.
Parents who do not speak English will only be
approached if an adult interpreter is available. Trust
interpreter and link worker services will be used to sup-
port involvement of participants whose first language is
not English.
A senior investigator will be available at all times to
discuss concerns raised by parents or clinicians during
the course of the trial. Mrs Huma Aziz, Service User
representative will also be available to talk to parents
who require further information from another parent
who has experience in participating in research.
Information about the study will continue to be
offered to parents after their infant leaves the unit. A
newsletter about the study will be disseminated at regu-
lar intervals.
Randomisation
Infants will be randomised following the decision to
extubate. Block randomisation will be used, stratified by
centre and gestation (< 28 weeks or ≥ 28 weeks). Web
based randomisation will be used.
Blinding
The n-BiPAP device produces an audible noise which
cannot be masked. Due to this, parents, clinicians
involved in patient care and researchers assessing study
end-points will not be blinded to the nature of the study
treatments. To reduce bias, criteria for extubation and
re-intubation have been defined and will be strictly
adhered to.
Minimisation of bias
This is an un-blinded randomised controlled trial. To
minimise bias ‘Criteria for extubation’ and ‘Criteria for
failure of extubation’ have been carefully defined. These
will be strictly adhered to throughout the trial. Rando-
misation will be conducted once the decision to extu-
bate has been taken. The time duration between
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and explanations sought where there is undue delay.
Auditing will also be done on adherence to ‘Criteria for




(1) Loaded with caffeine according to standard local
protocol (and)
(2) Satisfactory blood gases defined as pH of more
than 7.25 and partial pressure of carbon dioxide of less
than 7 kPa (52.5 mmHg). As most babies will not have
arterial access at the time of extubation we have not
defined partial pressure of oxygen in targeted blood gas
indices (and)
(3) Mean airway pressure of 7 cm water or less (and)
(4) Fractional inspired oxygen concentration of 35% or
less (and)
( 5 )G o o ds p o n t a n e o u sr e s p i r atory effort, persistently
higher than ventilator rate.
n-CPAP
The n-CPAP group will receive at extubation a single
level continuous positive airway pressure of 6 cm water
for at least 48 hours before weaning is commenced. If
the infant is stable for the preceding 24 hours defined
by having fewer than three minor apnoeas and no
increase in oxygen requirement, weaning will be per-
mitted. Minor apnoea will be defined as apnoea requir-
ing stimulation but not mask ventilation. CPAP will be
decreased from 6 cm water by 1 cm water every 48
hours if tolerated based on the above criteria. This will
be done until a pressure of 4 cm water is reached. If a
pressure of 4 cm water is successfully tolerated for 48
hours then time off n-CPAP will be allowed. Thereafter,
no fixed weaning regime based on number of hours in a
day the infant will be allowed to come off CPAP will be
prescribed.
n-BiPAP
The n-BiPAP group will receive at extubation a mean
airway pressure of 6 cm water (positive end expiratory
pressure of 4 cm water and peak inspiratory pressure of
8 cm of water). Inspiratory time of one second and
respiratory rate of 30/min will always be maintained. If
the infant is stable for the preceding 48 hours at mean
airway pressure of 6 cm water defined by having fewer
than 3 minor apnoeas and no increase in oxygen
requirement, weaning will be permitted. Minor apnoea
will be defined as apnoea requiring stimulation but not
mask ventilation.
The infant will then receive a mean airway pressure of
5 cm water (positive end expiratory pressure of 4 cm
water and peak inspiratory pressure of 6 cm of water). If
the infant is stable for the preceding 48 hours at mean
airway pressure of 5 cm water defined by having fewer
than 3 minor apnoeas and no increase in oxygen
requirement, weaning will be permitted. Minor apnoea
will be defined as apnoea requiring stimulation but not
mask ventilation.
The infant will then receive a CPAP of 4 cm water. If
the infant is stable for the preceding 48 hours at CPAP
of 4 cm water defined by having fewer than 3 minor
apnoeas and no increase in oxygen requirement, then
time of CPAP will be permitted. Minor apnoea will be
defined as apnoea requiring stimulation but not mask
ventilation. Thereafter, no fixed weaning regime based
on number of hours in a day the infant will be allowed
to come off CPAP will be prescribed.
Standards of care
Routine hourly monitoring of heart rate, peripheral oxy-
gen saturation and respiratory rate will be performed.
Delivered n-CPAP and n-BiPAP pressures will be moni-
tored regularly. Efforts will be made to maintain desired
CPAP and mean airway pressure levels in accordance
with standard nursing practice.
Criteria for failure of extubation
This will be defined as:
(1) Uncompensated respiratory acidosis defined as pH
less than 7.2 and partial pressure of carbon dioxide of
more than 8 kPa (60 mmHg) (or)
(2) Major apnoea requiring mask ventilation
Rescue treatment
Rescue treatment with n-BiPAP will not be allowed.
Mechanical ventilation through endotracheal tube will
be required when ‘Criteria for failure of extubation’ are
reached.
Data collection
All data for trial analysis are routine clinical items that
can be obtained from the clinical notes. Data will be
collected on trial-specific case report forms. Data will be
entered by the research nurse or Local principal investi-
gator on a web based electronic case record form pro-
vided by OpenCDMS. Access to the form will be
password protected and participants will be identified by
trial number only.
Clinical information will be collected at the following
times:
1. At trial entry: Information on eligibility; back-
ground information and randomisation
2. Following randomisation: Daily observations
regarding ventilation, vital signs, blood gases,
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de-saturations for 1 week after extubation
3. Follow-up: Data on duration of hospital stay,
duration of oxygen requirement, oxygen requirement
at 28 days and at 36 weeks corrected gestational age
and age at transfer back to referral centre, total
number of days on ventilator, n-CPAP and n-BiPAP
Further information will be collected on expected ser-
ious adverse events. No additional blood samples are
required for this study.
Statistical analysis
A formal statistical analysis plan and other covariates
will be pre-specified after a blinded review of the data.
The primary efficacy analysis will be conducted on an
intention to treat basis. The primary outcome variable is
a binary (yes/no) outcome variable and groups will be
compared using a logistic regression model adjusting for
the stratification variables and other covariates prior to
the review stage Other outcomes will be analysed using
analogous ordinary, ordinal or logistic regression mod-
els. Any formal sub-group analyses will be pre-planned
and based on specific interaction tests.
Interim analysis and termination of trial
No interim analyses are planned. If any such are advised
by the Data Monitoring Committee (DMC) an analysis
plan will be developed and agreed by the DMC and
Trial Steering Committee (TSC). Haybittle-Peto stop-
ping rules will be used.
Duration of study
540 infants will be recruited over 2.5 years. The trial will
terminate when the last recruited infant is discharged
from hospital or dies.
Quality control and quality assurance procedures
Compliance to protocol
Compliance will be defined as full adherence to proto-
col. Compliance with the protocol will be ensured by a
number of procedures as described below.
Site set-up and training
Start-up visits at each site, including training in trial
procedures, will be performed before the first infant is
enrolled.
Regular site visits will be made by the Trial co-ordina-
tor and/or the Chief Investigator or a delegated member
of the Trial Management Group to ensure adherence to
the protocol and to deal with any site specific issues. A
major focus of these visits will be the quality of data col-
lection, adherence to protocol and minimisation of bias.
Nurse study days will be undertaken to ensure that
nurses involved with the study are fully appraised of
issues such as consent, data collection issues and study
specific procedures.
Data processing and monitoring
All study data will be
1. Screened for out-of-range data, with cross-checks
for conflicting data within and between data collec-
tion forms by a data manager.
2. Referred back to relevant centre for clarification
in the event of missing items or uncertainty.
3. A random 10% of the data will be independently
validated against the source documents by the data
manager.
4. The Chief Investigator and trial statistician will
review the results generated for logic and for pat-
terns or problems. Outlier data will be investigated.
The Chief Investigator and Trial Statistician will
decide if any action needs to be taken.
Safety Definitions
Adverse event (AE)
Any untoward medical occurrence in a subject recruited
to a clinical trial, including occurrences which are not
necessarily caused by or related with the treatment. An
adverse event can be any unfavourable and unintended
sign or symptom associated with the use of the inter-
vention whether or not related to its use.
Serious adverse event (SAE)
Any adverse event that
a) Results in death
b) Is life-threatening
c) Requires hospitalisation or prolongation of existing
hospitalisation
d) Results in persistent or significant disability or
incapacity
Expected serious adverse events
Due to the high risk population of extremely prema-
ture infants with gestational age under 30 weeks, the
following are serious adverse events which could be
expected for this population during the course of the
study:
(1) Intraventricular haemorrhage defined as haemor-
rhage causing ventricular dilatation with or without
brain parenchymal involvement
(2) Periventricular leukomalacia on cranial ultrasound
scan imaging
(3) Necrotising enterocolitis requiring surgery
(4) Patent ductus arteriosus requiring treatment
(5) Retinopathy of prematurity requiring laser
treatment
(6) Pneumothorax within 7 days after extubation
(7) Evidence of traumatic nasal injury
(8) Death
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T h e s ew o u l db ea n ys e r i o u sa d v e r s ee v e n t st h a tw e r e
not expected to occur in this high risk population as
listed above.
Reporting of serious adverse events
All expected Serious Adverse Events will be recorded.
All expected serious adverse events whether or not they
are attributable to the study intervention will be
reviewed by the local principal investigator to determine
i ft h e r ei sr e a s o n a b l es u s p ected causal relationship to
the intervention. If there is evidence that there may be a
novel causal relationship with the intervention, then the
procedure for expedited reporting of serious adverse
events will be followed. All adverse events will be fol-
lowed until satisfactory resolution or until the investiga-
tor responsible for the care of the participant deems the
event to be chronic or the patient to be stable.
The DMC will receive an analysis of adverse events
(grouped by body system, severity and randomised
group) and overall safety data as part of the closed
report at its 6 monthly meeting. The DMC will review
the analysis and give recommendations to the TSC
when appropriate.
All unexpected serious adverse events whether or not
they are attributable to the study intervention will be
reviewed by the local principal investigator to determine
i ft h e r ei sr e a s o n a b l es u s p ected causal relationship to
the intervention. The Trial Management Group (TMG)
will regularly review unexpected SAEs reported and
send the forms monthly to the sponsor, except where a
causal relationship is suspected and expedited reporting
procedures are necessary.
Reporting of Serious Adverse Events with a suspected
causal relationship to the intervention
All Serious Adverse Events with a suspected causal rela-
tionship to the intervention will be reported to the
Chief Investigator within one working day of the discov-
ery or notification of the event.
The Chief Investigator will report all these events to
the Ethics Committee and Sponsor. Fatal or life threa-
tening SAEs with a suspected causal relationship will be
reported within 7 days and all other SAEs at monthly
intervals after TMG review. In addition a copy of the
SAE with a suspected causal relationship to the inter-
vention will be forwarded to the Chair of the Data Mon-
itoring Committee. The Chair will also be provided with
a document detailing all previous SAEs with their allo-
cation. The Chief Investigator will also inform all inves-
tigators concerned of relevant information about SAEs
that could adversely affect the safety of participants.
All SAEs with a suspected causal relationship to the
intervention that result in a participant’sw i t h d r a w a l
f r o mt h es t u d yo ra r ep r e s e n ta tt h ee n do ft h es t u d y
will be followed up until a satisfactory resolution occurs.
Trial governance
Trial Management Group (TMG)
This group including the user-representative will meet
bi-monthly to review trial safety and recruitment.
Trial Steering Committee (TSC)
A TSC will be set up which will have overall supervision
of the trial. It will meet prior to commencement of the
trial and then 6 monthly until completion. A meeting of
the TSC will be held within a month of every DMC
meeting to consider their recommendations.
Membership of the TSC will include members of the
TMG and Local Principal Investigators at recruiting
sites. Additional independent members in the committee
will also include a representative from the Sponsor, a
representative from the NIHR network and the local
Bliss Charity representative. The chair of the TSC will
be an independent member. Voting rights will be such
that there is equal representation from independent and
non-independent members.
Data Monitoring Committee (DMC)
An independent DMC will be formed and constituted
according to the DAMOCLES guidelines. This will
review safety data, recruitment, and event rates (sam-
ple size assumptions). The DMC will recommend if
any interim analysis of the study outcomes is neces-
sary and agree the timing and content of any such
analyses. A DMC Charter will be drawn up prior to
the start of the trial taking account of the DAMO-
CLES statement.
The DMC will report to the TMG and TSC. The
TMG will make decisions about the conduct of the
study and inform the TSC of significant issues. The
trial will be monitored in line with International Con-
ference on Harmonisation- Good Clinical Practice by
the Research and Development department at Central
Manchester University Hospitals NHS Foundation
Trust.
Research parent group (RPG)
The research parent group will meet around the same
time as Trial Steering Committee. The research team
will update them regarding progress since the last meet-
ing including, rate of recruitment, any adverse events
recorded and other trial related issues. The group will
then be allowed to discuss the project independently
with no researchers present. Following the discussion,
the group will be given an opportunity to provide their
feedback.
Trial status
Ethics Committee approval was granted on 4
th January
2011. Recruitment has commenced on 1
st July 2011.
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